Effects of tissue plasminogen activator administration on cholinergic and cognitive deficits in in a transgenic model of Alzheimer's disease-like amyloid pathology

组织纤溶酶原激活剂给药对阿尔茨海默病样淀粉样蛋白病理转基因模型中胆碱能和认知缺陷的影响

• 批准号: 311872
• 负责人: Pentz Rowan D
• 金额: $ 1.27万
• 依托单位: McGill University
• 依托单位国家: 加拿大
• 项目类别: Studentship Programs
• 财政年份: 2013
• 资助国家: 加拿大
• 起止时间: 2013-12-01 至 2014-12-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=311872&lang=en
• 关键词: Alzheimer'S; Basal Forebrain Cholinergic Nuclei; Cholinergic Synapses; Fear Conditioning; Immunohistochemistry; Morris Water Maze; Nerve Growth Factor; Tissue Plasminogen Activator; Transgenic; Western Blot

Alzheimer's disease is the most common form of dementia worldwide and affects over 500 000 Canadians today. Current treatments for Alzheimer's are not very effective. Unless new treatments are found, the number of AD sufferers in Canada is expected to ste

阿尔茨海默氏病是世界上最常见的痴呆症，今天影响了50多万加拿大人。目前对阿尔茨海默氏症的治疗不是很有效。除非找到新的治疗方法，否则加拿大的AD患者人数预计将增加。